PTO/SB/30 (05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE aperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number.

Request For Continued Examination (RCE) Transmittal

Address to: Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Application Number	09/898,751
Filing Date	07/02/2001
First Named Inventor	Wei Wang et al.
Art Unit	1647
Examiner Name	Bunner, Bridget E.
Attorney Docket Number	DX0882XK

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8. 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

Submission required under 37 CFR 1.114 Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).					
a. Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.					
i. Consider the arguments in the Appeal Brief or Rely Brief previously filed on					
b. Enclosed					
i. Amendment/Reply iii. Int	formation Disclosure Statement (IDS)				
ii. Affidavit(s)/ Declaration(s) iv. Ot	her Appendix A and B - 10 pages				
2. Miscellaneous					
Suspension of action on the above-identified application is requested u	* *				
a period of months. (Period of suspension shall not exceed 3 month	s; Fee under 37 CFR 1.17(i) required)				
b. Other					
The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No.					
i. RCE fee required under 37 CFR 1.17(e)					
ii. Extension of time fee (37 CFR 1.136 and 1.17)					
iii. Other					
b. Check in the amount of \$en	closed				
c. Payment by credit card (Form PTO-2038 enclosed)					
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
SIGNATURE OF APPLICANT, ATTORNEY, OR AG					
	Registration No. (Attorney/Agent) 45,997 Date November 20, 2003				
CERTIFICATE OF MAILING OR TRANSMISSION I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope					
addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.					
Name (Print/Type)					
Signature	Date				

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a densitied which is to life (and by the DSFTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mall Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/17 (10-03)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it displays a valid OMB control supplies.

Under the Reperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid QMB control number.					
FEE TRANSMITTAL	> 6 A 115757 A 1	C mplete if Known			
		Application Number	09/898,751		
FOR FY 2004 Effective 10/01/2003. Patent fees are subject to annual revision. Applicant claims small entity status. See 37 CFR 1.27		Filing Date	07/02/2001		
		First Named Inventor	Wei Wang et al.		
		Examiner Name	Bunner, Bridget E.		
		Art Unit	1647		
TOTAL AMOUNT OF PAYMENT	(\$) 1720.00	Attorney Docket No.	DX0882XK		
FEE CALCULATION () AND A STORY ()			ALOUI ATION (

METHOD OF PAYMENT (check all that apply)	FEE CALCULATION (continued)					
Check Credit card Money Other None	None 3. ADDITIONAL FEES					
Order Order	Large Entity Small Entity					
Deposit Account:	Fee Fee Fee Fee Description Code (\$)	Fee Paid				
Account 19-0365	1051 130 2051 65 Surcharge - late filing fee or oath	<u> </u>				
Deposit Account Schering-Plough Corporation	1052 50 2052 25 Surcharge - late provisional filing fee or cover sheet					
Name The Director is authorized to: (check all that apply)	1053 130 1053 130 Non-English specification	 				
Charge fee(s) indicated below Credit any overpayments	1812 2,520 1812 2,520 For filing a request for ex parte reexamination	LI				
Charge any additional fee(s) or any underpayment of fee(s)	1804 920" 1804 920" Requesting publication of SIR prior to Examiner action	<u> </u>				
Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.	1805 1,840* 1805 1,840* Requesting publication of SIR after Examiner action					
FEE CALCULATION	1251 110 2251 55 Extension for reply within first month					
	1252 420 2252 210 Extension for reply within second month					
1. BASIC FILING FEE Large Entity Small Entity	1253 950 2253 475 Extension for reply within third month	950.00				
Fee Fee Fee Fee Description Fee Paid	1254 1,480 2254 740 Extension for reply within fourth month					
Code (\$) Code (\$)	1255 2,010 2255 1,005 Extension for reply within fifth month					
1001 770 2001 385 Utility filing fee 1002 340 2002 170 Design filing fee	1401 330 2401 165 Notice of Appeal					
1002 540 2002 170 Design ming its	1402 330 2402 165 Filing a brief in support of an appeal					
1003 330 2003 203 Frank ming lee	1403 290 2403 145 Request for oral hearing					
1004 770 2004 385 Reissue ming lee	1451 1,510 1451 1,510 Petition to institute a public use proceeding					
	1 1452 110 2452 55 Petition to revive - unavoidable					
SUBTOTAL (1) (\$)	1453 1,330 2453 665 Petition to revive - unintentional					
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	E 1501 1,330 2501 665 Utility issue fee (or reissue)					
Fee from Ext <u>ra Claims below Fee Palo</u>						
Total Claims20** = X =	1503 640 2503 320 Plant issue fee	<u> </u>				
Independent - 3** = X = =	1460 130 1460 130 Petitions to the Commissioner					
Multiple Dependent	1807 50 1807 50 Processing fee under 37 CFR 1.17(q)					
Large Entity Small Entity	1806 180 1806 180 Submission of Information Disclosure Stmt					
Fee Fee Fee Fee Description Code (\$)	8021 40 8021 40 Recording each patent assignment per property (times number of properties)					
1202 18 2202 9 Claims in excess of 20 1201 86 2201 43 Independent claims in excess of 3	1809 770 2809 385 Filing a submission after final rejection (37 CFR 1.129(a))					
1203 290 2203 145 Multiple dependent claim, if not paid	1810 770 2810 385 For each additional invention to be					
1204 86 2204 43 ** Reissue independent claims over original patent	examined (37 CFR 1.129(b)) 1801 770 2801 385 Request for Continued Examination (RCE)	770.00				
1205 18 2205 9 ** Reissue claims in excess of 20 and over original patent	1802 900 1802 900 Request for expedited examination of a design application					
	Other fee (specify)					
SUBTOTAL (2) (\$) **or number previously paid, if greater; For Reissues, see above* *Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 1720.00						
SUBMITTED BY (Complete (if applicable))						
	Pociatorian No.					

Name (Print/Type) SANDY ZARADIC Telephone 908-298-7221 (Attomey/Agent) November 20, 2003 Signature

WARNING: Information on this form may become public. Credit card information should not b included n this f m. Provid credit card inf rmati n and auth rizati n n PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PATENT CASE: DX0882XK
THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Wei Wang et al. : Examiner: Bu

Examiner: Bunner, Bridget E.

For: Chemokine and Receptor Uses;

Group Art Unit: 1647

Compositions; Methods

Serial No.: 09/898,751

Filing Date: July 2, 2001

November 20, 2003

Mail Stop: RCE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

RESPONSE TO OFFICE ACTION

This is in response to the Office Action, Paper No. 14, (Confirmation No. 7429) mailed May 20, 2003, for which a response was due <u>August 20, 2003</u>. A Petition under 37 C.F.R. § 1.136 to extend the time of response by three months, up to and including <u>November 20, 2003</u>, together with provision for payment of the required petition fee is enclosed herewith.

Please amend the application as detailed below.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 4 of this paper.

Appendix A contains publication abstracts that support a nexus between CTACK and allergic-contact dermatitis, psoriasis, wound healing, and carcinoma.

Appendix B contains data that provides additional evidence of a nexus between CTACK and a carcinoma as well as the therapeutic effect of an antibody against CTACK on a carcinoma in vivo.